NCT05650060View on ClinicalTrials.gov

Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

CompletedOBSERVATIONAL
Enrollment

163

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

December 23, 2021

Study Completion Date

December 23, 2021

Conditions
Plaque Psoriasis
Interventions
DRUG

Secukinumab

all patients with psoriasis who received secukinumab

Trial Locations (1)

Unknown

Novartis Investigative Site, Bangkok

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY